Immunis Stock

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.

Sign up today and learn more about Immunis Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Immunis Stock

Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.

Funding History

August 2022$10.0M

Management

Chief Artificial Intelligence Officer

Neil Sahota

Chairman of the Board of Directors

Hans Keirstead

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo